Press Room

Webinar - AMLM: the perks of method performance verification in pharmaceutical quality framework

Start
Thursday, October 22, 2020 - 16:00
End
Thursday, October 22, 2020 - 16:00
Location: online

Thursday, October 22nd, 2020 | 12 PM (EDT), 4 PM (BST), 5 PM (CEST)

 

Watch On-Demand Webinar

 

Speakers

Lúcia Volta e Sousa - Analytical Chemist, R&D Analytical Development
Nuno Matos - Director, Quality System Management

 

Analytical Method Lifecycle Management (AMLM) principles require a holistic perspective where method robustness is considered together with process and product variability. AMLM views all method related activities as a continuum and interrelated multi-step process, where knowledge and risk management are the key enablers.

This includes three stages, Method design (Stage 1), qualification (Stage 2) and Performance Verification (Stage 3). All knowledge gathered in Stage 1 and 2 allow an effective definition of the Analytical Control Strategy (ACS), that provides directly the performance parameters that can be continuously monitored on Stage 3. In contrast to the first two stages, Stage 3 offers the possibility of an enhanced data set to collect, analyze and evaluate method performance. This promotes a continuous method evaluation, ensuring it remains fit for the intended purpose or, if not, supports the corrective actions required for method improvement. Moreover, this monitoring program should be aligned with the Quality Management System (QMS) in place, since it includes an efficient change control and deviation management system.

With this webinar an overview of AMLM Stage 3 will be presented, including its implications, advantages and case studies, and its capturing within the current QMS. Additionally, regulatory and industry initiatives that mark the evolution of these concepts and capture the current and future expectation of pharmaceutical framework will be highlighted.

 

In this webinar you’ll learn:

  • Analytical Method Lifecycle Management

  • Method Performance verification program

  • ICH Q14 and Q12

  • USP 1220>

 

Watch On-Demand Webinar

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026